Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
The Foundry is a medical device incubator that identifies unmet clinical needs and builds companies around new technologies to address them, working with physician collaborators to develop products from concept to market. It operates a facility with office space, R&D and wet labs, chemistry development, a machine shop, and a clean room.
2 investors
2 investors
Therorna develops circular RNA-based therapeutic candidates and preventive medicines for diseases with unmet clinical needs. The company was founded in 2021 by domestic experts and overseas-educated PhDs to advance circular RNA technology in drug discovery and therapy.
2 investors
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering. The company is led by a team with a track record of 35+ drug approvals.
2 investors
Thymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease. The company is building a pipeline of off-the-shelf cell therapies for immunodeficiencies, transplant-related, and autoimmune disorders.
2 investors
Tisento develops pharmaceutical treatments for complex genetic mitochondrial diseases, beginning with MELAS. The company is led by a team of industry veterans focused on improving outcomes for patients with life-altering rare genetic conditions.
2 investors
Tium Bio develops immunotherapy drugs for treating rare and intractable diseases. The company focuses on oncology indications including head and neck cancer, with a pipeline of differentiated candidates in clinical development.
2 investors
Tolemy Bio provides a software platform for teams to model, simulate, and optimize biological systems across cell biology, advanced therapeutics, and bioprocessing applications.
2 investors
Topo Therapeutics is a drug discovery company developing treatments targeting ion channels and transmembrane proteins for conditions such as pain, epilepsy, and CNS, pulmonary, and renal diseases. It is built around scientific advisors and leadership with expertise in ion channel biology and biophysics.
2 investors
Toro Bio develops automated systems for cell and gene therapy production at point of care, enabling personalized cancer therapies. The company focuses on streamlining process development and manufacturing for therapeutic applications.
2 investors
Tr1X is a biopharmaceutical company developing cell and gene therapies to cure autoimmune and inflammatory diseases with high unmet medical need. The company translates scientific discoveries in immune regulation and regenerative medicine into novel patient therapies.
2 investors
Trace Biosciences develops technology to make nerves visible in real time during surgical procedures, enabling surgeons to better identify and preserve nerve structures. The company targets operating rooms with fluorescent imaging agents and related surgical visualization tools.
2 investors
TrackPaw Scientific develops an automated digital animal tracking system for preclinical drug development laboratories, providing real-time monitoring and data collection to improve animal welfare and research data quality. The platform serves pharmaceutical and biotechnology companies conducting preclinical research.
2 investors
TRACON Pharmaceuticals was a biopharmaceutical company that is currently undergoing liquidation and dissolution as of November 2024.
2 investors
TrakCel develops technology solutions for clinical trial services and cell therapy supply chain management, including cold chain logistics and software platforms for advanced therapy deployment. The company serves pharmaceutical companies and advanced therapy developers managing complex patient-centric operations globally.
2 investors
Transcera is a biotech company developing a new class of therapeutics that use lipid trafficking pathways to direct extracellular proteins into lysosomes for degradation, aimed at treating chronic diseases. Its platform combines a lysosome-targeting lipid, a chemical linker, and a peptide or protein binder to degrade soluble and membrane proteins across tissues.
2 investors
Transcripta Bio develops medicines for patients with serious diseases by mapping how molecules affect human cells at single-cell resolution. Its drug discovery platform draws on single-cell genomics and AI for biology.
2 investors
Transition Metal Solutions applies microbial and biochemical methods to enhance copper extraction from low-grade ores, enabling more efficient recovery with reduced environmental impact for mining operations. The company works within existing mining infrastructure rather than replacing it, targeting the growing copper demand from the energy transition.
2 investors
Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases. Its lead investigational candidate, TTHX1114, is being studied in a Phase 2 trial for improving visual recovery after Descemet Stripping Only (DSO) procedures.
2 investors
Trestle Biotherapeutics develops bioengineered implantable tissues designed to treat end-stage renal disease, aiming to get patients off dialysis and eventually provide replacement organs. The company uses stem cell biology, biofabrication, and 3D bioprinting technologies to create functional kidney tissue for patients with kidney failure.
2 investors
Formation Bio develops drugs alongside research site partners, including health systems, academic medical centers, and independent research sites, with a focus on accelerating clinical trials in dermatology, rheumatology, and cardiometabolic diseases. The company provides technology solutions, monitoring services, and enrollment support to streamline the drug development process.
2 investors
2 investors
Pfizer is a pharmaceutical company that researches, develops, and manufactures medicines and vaccines to treat and prevent diseases. It also runs patient assistance programs and global health access initiatives.
2 investors
Trince is a Ghent University spin-off developing photoporation technology for physical transfection of cells as an alternative to viral vectors and electroporation. Its technology, including the Lumipore platform, targets R&D, manufacturing, and GMP-compliant clinical applications such as cell and gene therapy.
2 investors